FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2157620753> ?p ?o ?g. }

• W2157620753 endingPage "F1365" @default.
• W2157620753 startingPage "F1354" @default.
• W2157620753 abstract "Erythropoietin (Epo) induces erythrocytosis by suppressing erythroid progenitor cell apoptosis through the Janus-activated kinase-signal transducers and activators of transcription (JAK-STAT) pathway. Since apoptosis contributes to cisplatin (CP)-induced nephrotoxicity and Epo receptors (EpoR) are expressed in the kidney, we examined the role of antiapoptosis in recombinant human erythropoietin (rHuEpo)-mediated renal protection. In human renal proximal tubular epithelial (RPTE) cells in culture, rHuEpo, but not inactive rHuEpo (I-rHuEpo), the receptor-binding sites of which are mutated, caused a significant reduction in CP-induced apoptosis at ≥100 U/ml. rHuEpo, but not I-rHuEpo, increased STAT5 and Akt/PKB phosphorylation, demonstrating functional EpoR expression on RPTE cells. Furthermore, the JAK2 inhibitor tyrphostin AG-490 attenuated rHuEpo protection, suggesting a role of the JAK-STAT pathway in rHuEpo-mediated antiapoptosis. In rats, intravenous administration of 5,000 U/kg rHuEpo, but not an equivalent peptide mass of I-rHuEpo, before a single 5.5 mg/kg iv injection of CP, significantly increased hematocrit (Hct) and reduced the CP-induced increase in serum creatinine. Serum creatinine on day 4 was 3.4 ± 0.3, 1.9 ± 0.3, and 3.5 ± 0.4 mg/dl in the CP, CP + rHuEpo, and CP + I-rHuEpo groups, respectively. Similarly, darbepoietin-α (DA), a hyperglycosylated analog of rHuEpo with prolonged in vivo activity when injected at 25 μg/kg iv before CP, significantly increased Hct and reduced serum creatinine. Renal clearance studies based on glomerular filtration rate and renal blood flow confirmed the significant renal protection by DA against CP. Tubular apoptosis and necrosis were significantly reduced in the kidneys of the CP + DA vs. the CP + saline group. Moreover, the equalization of Hct by venesection did not abrogate the DA-mediated renal protection. Administration of DA 48 h after CP injection also conferred significant renal protection. Thus our experiments confirm a role for erythropoiesis-stimulating proteins, including the new analog DA, in limiting CP-induced nephrotoxicity and suggest that antiapoptosis via the Epo-EpoR interaction is an important mechanism for renal protection." @default.
• W2157620753 created "2016-06-24" @default.
• W2157620753 creator A5004952857 @default.
• W2157620753 creator A5005594899 @default.
• W2157620753 creator A5009383094 @default.
• W2157620753 creator A5042481555 @default.
• W2157620753 creator A5043302676 @default.
• W2157620753 creator A5047550896 @default.
• W2157620753 creator A5051845397 @default.
• W2157620753 creator A5057662253 @default.
• W2157620753 date "2008-06-01" @default.
• W2157620753 modified "2023-10-17" @default.
• W2157620753 title "Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury" @default.
• W2157620753 cites W1504583940 @default.
• W2157620753 cites W1530591884 @default.
• W2157620753 cites W1538959048 @default.
• W2157620753 cites W1749117680 @default.
• W2157620753 cites W1973560198 @default.
• W2157620753 cites W1974106801 @default.
• W2157620753 cites W1989694397 @default.
• W2157620753 cites W1991321269 @default.
• W2157620753 cites W2007983312 @default.
• W2157620753 cites W2026112841 @default.
• W2157620753 cites W2037887947 @default.
• W2157620753 cites W2039237674 @default.
• W2157620753 cites W2039975110 @default.
• W2157620753 cites W2058141781 @default.
• W2157620753 cites W2071120706 @default.
• W2157620753 cites W2072453311 @default.
• W2157620753 cites W2075106455 @default.
• W2157620753 cites W2080423276 @default.
• W2157620753 cites W2095861062 @default.
• W2157620753 cites W2096208007 @default.
• W2157620753 cites W2108089603 @default.
• W2157620753 cites W2108511043 @default.
• W2157620753 cites W2109723592 @default.
• W2157620753 cites W2125806058 @default.
• W2157620753 cites W2137002490 @default.
• W2157620753 cites W2159063843 @default.
• W2157620753 cites W2162264368 @default.
• W2157620753 cites W2164837040 @default.
• W2157620753 cites W2170023789 @default.
• W2157620753 cites W2170110528 @default.
• W2157620753 cites W2245961525 @default.
• W2157620753 cites W4252764622 @default.
• W2157620753 cites W75111957 @default.
• W2157620753 doi "https://doi.org/10.1152/ajprenal.00131.2008" @default.
• W2157620753 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18385271" @default.
• W2157620753 hasPublicationYear "2008" @default.
• W2157620753 type Work @default.
• W2157620753 sameAs 2157620753 @default.
• W2157620753 citedByCount "49" @default.
• W2157620753 countsByYear W21576207532012 @default.
• W2157620753 countsByYear W21576207532013 @default.
• W2157620753 countsByYear W21576207532014 @default.
• W2157620753 countsByYear W21576207532015 @default.
• W2157620753 countsByYear W21576207532017 @default.
• W2157620753 countsByYear W21576207532018 @default.
• W2157620753 countsByYear W21576207532020 @default.
• W2157620753 countsByYear W21576207532021 @default.
• W2157620753 countsByYear W21576207532022 @default.
• W2157620753 countsByYear W21576207532023 @default.
• W2157620753 crossrefType "journal-article" @default.
• W2157620753 hasAuthorship W2157620753A5004952857 @default.
• W2157620753 hasAuthorship W2157620753A5005594899 @default.
• W2157620753 hasAuthorship W2157620753A5009383094 @default.
• W2157620753 hasAuthorship W2157620753A5042481555 @default.
• W2157620753 hasAuthorship W2157620753A5043302676 @default.
• W2157620753 hasAuthorship W2157620753A5047550896 @default.
• W2157620753 hasAuthorship W2157620753A5051845397 @default.
• W2157620753 hasAuthorship W2157620753A5057662253 @default.
• W2157620753 hasConcept C126322002 @default.
• W2157620753 hasConcept C134018914 @default.
• W2157620753 hasConcept C159641895 @default.
• W2157620753 hasConcept C170493617 @default.
• W2157620753 hasConcept C185592680 @default.
• W2157620753 hasConcept C190283241 @default.
• W2157620753 hasConcept C2778248108 @default.
• W2157620753 hasConcept C2778534260 @default.
• W2157620753 hasConcept C2779703530 @default.
• W2157620753 hasConcept C2780091579 @default.
• W2157620753 hasConcept C2780959883 @default.
• W2157620753 hasConcept C31102739 @default.
• W2157620753 hasConcept C32465701 @default.
• W2157620753 hasConcept C55493867 @default.
• W2157620753 hasConcept C71924100 @default.
• W2157620753 hasConceptScore W2157620753C126322002 @default.
• W2157620753 hasConceptScore W2157620753C134018914 @default.
• W2157620753 hasConceptScore W2157620753C159641895 @default.
• W2157620753 hasConceptScore W2157620753C170493617 @default.
• W2157620753 hasConceptScore W2157620753C185592680 @default.
• W2157620753 hasConceptScore W2157620753C190283241 @default.
• W2157620753 hasConceptScore W2157620753C2778248108 @default.
• W2157620753 hasConceptScore W2157620753C2778534260 @default.
• W2157620753 hasConceptScore W2157620753C2779703530 @default.
• W2157620753 hasConceptScore W2157620753C2780091579 @default.
• W2157620753 hasConceptScore W2157620753C2780959883 @default.
• W2157620753 hasConceptScore W2157620753C31102739 @default.

• next